Lupin inches up on launching authorized generic version of Brovana in United States

04 Jun 2021 Evaluate

Lupin is currently trading at Rs. 1234.00, up by 1.65 points or 0.13% from its previous closing of Rs. 1232.35 on the BSE.

The scrip opened at Rs. 1245.00 and has touched a high and low of Rs. 1249.80 and Rs. 1223.60 respectively. So far 29789 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1267.50 on 02-Jun-2021 and a 52 week low of Rs. 828.65 on 27-Jul-2020.

Last one week high and low of the scrip stood at Rs. 1267.50 and Rs. 1190.55 respectively. The current market cap of the company is Rs. 55920.46 crore.

The promoters holding in the company stood at 46.86%, while Institutions and Non-Institutions held 40.46% and 12.69% respectively.

Lupin has launched the authorized generic version of Brovana (arformoterol tartrate) Inhalation Solution 15 mcg?/2 mL, unit-dose vials, of Sunovion Pharmaceuticals Inc.
Arformoterol Tartrate Inhalation Solution 15 mcg/2 mL, is indicated for the long-term, twice daily (morning and evening) maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. It is for use by nebulization only.

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India.

Lupin Share Price

2147.65 0.05 (0.00%)
28-Jan-2026 09:09 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1638.90
Dr. Reddys Lab 1240.05
Cipla 1315.00
Zydus Lifesciences 890.75
Lupin 2147.65
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×